Search results
Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants – nimble and focused biopharmaceutical and health technology ...
May 30, 2024 · Press Releases. Year. 2024. May 30, 2024. Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update. May 16, 2024. Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024. April 2, 2024.
Dec 1, 2022 · About Roivant Sciences Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants – nimble and focused biopharmaceutical and health technology companies.
With employees living and working in over 30 states, we lean into supporting and enabling our employees' preferred work environments with in-office, hybrid and remote work opportunities; providing extensive in-office perks, remote work stipends and commuter benefits. New York. 151 W 42nd Street. 15th Floor.
Roivant Sciences | 25,893 followers on LinkedIn. Reinventing Biopharma | Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by ...
Oct 1, 2021 · About Roivant Sciences Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch 'Vants' – nimble and focused biopharmaceutical and health technology companies.
May 30, 2024 · Roivant Sciences, the Healthcare sector company, was revisited by a Wall Street analyst on May 29. Analyst David Risinger from Leerink Partners reiterated a Buy rating on the stock and has a $17.00 price target. David Risinger has given his Buy rating due to a combination of factors including the updated market model for Roivant Sciences’s ...
